Dmitry Balyasny Balyasny Asset Management
Dmitry Balyasny is the founder of Balyasny Asset Management, a major multi-strategy and multi-manager hedge fund platform. The firm allocates capital across fundamental equities, macro, quant, and other teams under a central risk framework. Balyasny’s platform is often cited alongside other leading pod-shop multi-strategy firms.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Marathon Petroleum
MPC
|
+$152M |
| 2 |
AT&T
T
|
+$119M |
| 3 |
Norfolk Southern
NSC
|
+$117M |
| 4 |
CSX Corp
CSX
|
+$115M |
| 5 |
Booking.com
BKNG
|
+$104M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$187M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$156M |
| 3 |
C.H. Robinson
CHRW
|
+$134M |
| 4 |
PARA
Paramount Global Class B
PARA
|
+$130M |
| 5 |
BCR
CR Bard Inc.
BCR
|
+$100M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 18.4% |
| 2 | Industrials | 9.75% |
| 3 | Financials | 7.9% |
| 4 | Consumer Staples | 7.89% |
| 5 | Healthcare | 7.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
HA
1076
DELISTED
Hawaiian Holdings, Inc.
HA
| $240K | ﹤0.01% |
5,090
-196,588
| -97% | -$7.62M |
|
1077
BGC Group
BGC
$5.68B
| $239K | ﹤0.01% |
41,068
-76,335
| -65% | -$438K |
|
|
PCBK
1078
DELISTED
Pacific Continental Corp
PCBK
| $238K | ﹤0.01% |
+14,745
| New | +$226K |
|
1079
Hain Celestial
HAIN
$75.8M
| $237K | ﹤0.01% |
+5,796
| New | +$218K |
|
1080
Scholastic
SCHL
$760M
| $236K | ﹤0.01% |
+6,320
| New | +$225K |
|
1081
Constellation Brands
STZ
$23.5B
| $236K | ﹤0.01% |
1,560
-199,767
| -99% | -$28.9M |
|
1082
Verisk Analytics
VRSK
$24.7B
| $235K | ﹤0.01% |
2,940
-1,610
| -35% | -$118K |
|
1083
Marcus & Millichap
MMI
$1.23B
| $233K | ﹤0.01% |
9,190
-4,070
| -31% | -$95.4K |
|
|
HOUS
1084
DELISTED
Anywhere Real Estate
HOUS
| $232K | ﹤0.01% |
6,430
-1,970
| -23% | -$64.5K |
|
1085
3M
MMM
$92.3B
| $231K | ﹤0.01% |
+1,656
| New | +$213K |
|
|
CVC
1086
DELISTED
CABLEVISION SYS CP NY GRP CL-A
CVC
| $231K | ﹤0.01% |
+6,990
| New | +$225K |
|
|
VTLE
1087
DELISTED
Vital Energy
VTLE
| $230K | ﹤0.01% |
1,453
-38,911
| -96% | -$5.29M |
|
|
MSGN
1088
DELISTED
MSG Networks Inc.
MSGN
| $229K | ﹤0.01% |
+13,220
| New | +$231K |
|
1089
Fastenal
FAST
$58.8B
| $228K | ﹤0.01% |
+18,600
| New | +$202K |
|
1090
Worthington Enterprises
WOR
$2.78B
| $228K | ﹤0.01% |
+10,391
| New | +$199K |
|
|
AXLL
1091
DELISTED
AXIALL CORP COM STK (DE)
AXLL
| $226K | ﹤0.01% |
+10,340
| New | +$182K |
|
1092
Pilgrim's Pride
PPC
$7.57B
| $225K | ﹤0.01% |
9,880
-1,845,667
| -99% | -$42.8M |
|
1093
Federal Signal
FSS
$7.31B
| $223K | ﹤0.01% |
16,800
+2,450
| +17% | +$33.7K |
|
1094
Live Nation Entertainment
LYV
$43B
| $220K | ﹤0.01% |
9,870
-24,360
| -71% | -$532K |
|
1095
Movado Group
MOV
$772M
| $220K | ﹤0.01% |
+7,989
| New | +$214K |
|
|
XENT
1096
DELISTED
Intersect ENT, Inc
XENT
| $220K | ﹤0.01% |
+11,580
| New | +$210K |
|
|
TIF
1097
DELISTED
Tiffany & Co.
TIF
| $220K | ﹤0.01% |
+2,995
| New | +$201K |
|
1098
Bio-Rad Laboratories Class A
BIO
$10.2B
| $219K | ﹤0.01% |
+1,600
| New | +$210K |
|
1099
Emergent Biosolutions
EBS
$266M
| $219K | ﹤0.01% |
6,031
+600
| +11% | +$21.2K |
|
1100
Hasbro
HAS
$13.5B
| $219K | ﹤0.01% |
+2,740
| New | +$204K |
|
Similar funds
Dmitry Balyasny's Q1 2016 Portfolio in Review
As of Q1 2016, Dmitry Balyasny held 1,764 positions worth $16.8B, up 17% from $14.4B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Dmitry Balyasny deployed $2.2B of net new capital in Q1 2016, opening 564 new positions and adding to 341 existing holdings. Its largest new stake was Norfolk Southern: 1,546,641 shares worth $129M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 18% of assets, up from 16% a quarter earlier, followed by Industrials and Financials.
On the sell side, the largest reduction was Teva Pharmaceuticals, an estimated $187M trimmed.
- Dmitry Balyasny's largest Q1 2016 buy was Norfolk Southern: 1,546,641 shares worth $129M.
- Dmitry Balyasny added most to Marathon Petroleum in Q1 2016, an estimated $152M increase.
- Dmitry Balyasny's biggest Q1 2016 reduction was Teva Pharmaceuticals, cutting an estimated $187M.
- Dmitry Balyasny fully exited Union Pacific in Q1 2016, selling an estimated $79.7M.
- Dmitry Balyasny's ten largest holdings make up 12% of its $16.8B portfolio in Q1 2016.
- Dmitry Balyasny opened 564 new positions and closed 526 in Q1 2016.
- Dmitry Balyasny's portfolio value rose 17% quarter-over-quarter to $16.8B.
Based on Balyasny Asset Management's 13F filing for Q1 2016, filed 16 May 2016.